Menopause
Menopause symptom severity tied to race, ethnicity, regardless of socioeconomic status
Regardless of socioeconomic status, menopause symptom severity was associated with race and ethnicity, highlighting differences in symptom experiences, according to study results published in Menopause.
Menopause may unmask vulnerability to Alzheimer’s disease, other dementias
BOSTON — Menopause is a neurologic transition involving metabolic and immune systems of the brain, and timely estrogen therapy could reduce the risk for developing dementias and other neurogenerative diseases, according to a speaker.
VIDEO: Women’s heart disease risk factors should be assessed during menopause transition
In this Healio video exclusive, a speaker at the National Lipid Association Scientific Sessions discusses opportunities for heart disease prevention in women at the time of menopause transition.
Q&A: At 20 years, WHI emphasizes personalized postmenopausal care, shared decision-making
Results of Women’s Health Initiative trials highlight the importance of personalized health care in combination with shared decision-making for postmenopausal women, according to a review published in JAMA.
Q&A: Stigma, fear drive spread of menopause misinformation on social media
SAN FRANCISCO — Health care providers must combat menopause misinformation on social media by providing evidence-based information at visits and on online platforms, according to presenters at the ACOG Annual Clinical & Scientific Meeting.
Physical activity tied to greater odds of objective, subjective hot flashes
Acute increases in physical activity were associated with greater odds of objective and subjective hot flashes during waking and sleeping periods, according to findings published in Menopause.
Type of menopausal hormone therapy may influence cancer risk
CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.
OASIS: Fewer, less severe hot flashes observed with nonhormonal elinzanetant
SAN FRANCISCO — In two phase 3 trials, the nonhormonal investigational agent elinzanetant was associated with decreased frequency and severity of menopausal vasomotor symptoms over 12 weeks with a favorable safety profile.
ACOG meeting to focus on leadership, overcoming obstetrics, gynecology obstacles
This year’s ACOG Annual Clinical & Scientific Meeting will focus strongly on the importance of leadership to create change, providing attendees with more high-impact and fewer concurrent sessions.
Oral lasofoxifene associated with improved vulvovaginal atrophy symptoms in menopause
Postmenopausal women assigned daily oral lasofoxifene had significant and clinically meaningful improvements in vulvovaginal atrophy symptoms with a favorable safety profile, researchers reported in Menopause.